@article{bakal_bai_stoskopf_2004, title={Pharmacokinetics of sulfadimethoxine and ormetoprim in a 5 : 1 ratio following intraperitoneal and oral administration, in the hybrid striped bass (Morone chrysops x Morone saxitalis)}, volume={27}, ISSN={["0140-7783"]}, DOI={10.1046/j.0140-7783.2003.00540.x}, abstractNote={Selected pharmacokinetic parameters for sulfadimethoxine and ormetoprim, administered in a 5:1 ratio, via the oral and intraperitoneal (i.p.) routes were determined in the hybrid striped bass (Morone chrysops x Morone saxitalis). Plasma concentrations of both drugs were determined by high-performance liquid chromatography. A first-order one-compartment model adequately described plasma drug disposition. The elimination half-lives for sulfadimethoxine following i.p. and oral administration were 26 and 10.5 h, respectively. The half-lives for ormetoprim administered via i.p. and oral routes were 7.5 and 3.9 h, respectively. Cmax for sulfadimethoxine via the i.p. and oral routes were calculated to be 27.7 (+/-9.0) microg/mL at 3.6 h and 3.2 (+/-1.2) microg/mL at 1.2 h, respectively. Cmax for ormetoprim via the i.p. route was calculated to be 1.2 (+/-0.5) microg/mL at 9.1 h and 1.58 (+/-0.7) microg/mL at 5.7 h for the oral route. The oral availability of sulfadimethoxine relative to the i.p. route was 4.6%, while the oral availability of ormetoprim relative to the i.p. route was 78.5%. Due to the nonconstant ratio of these drugs in the plasma of the animal, the actual drug ratio to use for determining minimum inhibitory concentration (MIC) is unclear. Using the ratio of the total amount of each drug that is absorbed as a surrogate for the mean actual ratio may be the best alternative to current methods. Using this ratio as determined in these studies, (2.14:1 sulfadimethoxine:ormetoprim) to determine the MICs the single 50 mg/kg oral dose of the 5:1 combination of sulfadimethoxine and ormetoprim appears to provide plasma concentrations high enough to inhibit the growth of Yersinia ruckeri, Edwardsiella tarda, and Escherichia coli.}, number={1}, journal={JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS}, author={Bakal, RS and Bai, SA and Stoskopf, MK}, year={2004}, month={Feb}, pages={1–6} }
 @article{lankford_bai_goldstein_2000, title={Cloning of canine cytochrome P450 2E1 CDNA: identification and characterization of two variant alleles}, volume={28}, number={8}, journal={Drug Metabolism and Disposition}, author={Lankford, S. M. and Bai, S. A. and Goldstein, J. A.}, year={2000}, pages={981–986} }
 @article{blaisdell_goldstein_bai_1998, title={Isolation of a new canine cytochrome P450 cDNA from the cytochrome P450 2C subfamily (CYP2C41) and evidence for polymorphic differences in its expression}, volume={26}, number={3}, journal={Drug Metabolism and Disposition}, author={Blaisdell, J. and Goldstein, J. A. and Bai, S. A.}, year={1998}, pages={278–283} }
 @article{piscopo_farin_bai_1997, title={Determination of concentration of albendazole sulfoxide in plasma and uterine fluid of heifers}, volume={58}, number={1}, journal={American Journal of Veterinary Research}, author={Piscopo, S. E. and Farin, C. E. and Bai, S. A.}, year={1997}, pages={62–65} }
 @article{lankford_plummer_hellyer_christ_bai_1997, title={Pharmacokinetic-pharmacodynamic relations of losartan and EXP3174 in a porcine animal model}, volume={30}, ISSN={["1533-4023"]}, DOI={10.1097/00005344-199711000-00008}, abstractNote={The pharmacokinetics of losartan and EXP3174, an active metabolite of losartan, were evaluated in the anesthetized pig after both a single intravenous dose (3 mg/kg) and during constant intravenous infusion. The pharmacodynamic activities of losartan and EXP3174 were determined during constant intravenous infusion as the degree of inhibition of angiotensin II-induced increase in the diastolic pressure. The systemic plasma clearance of losartan was 22.1 +/- 4.4 ml/min/kg (mean +/- SEM) and had an apparent volume of distribution at steady state of 0.56 +/- 0.16 L/kg after a 3-mg/kg intravenous dose. The elimination half-life of losartan was 40 +/- 6 min. Less than 2% of the intravenous losartan doses was estimated to be present as unconjugated EXP3174. The plasma clearance of EXP3174 was approximately 50% that of losartan, 11.8 +/- 1.5 ml/min/kg, and had a smaller steady-state apparent volume of distribution, 0.18 +/- 0.04 L/kg. The elimination half-life for EXP3174 was slightly longer than that of losartan (52 min). The time course of the pharmacodynamic effects of losartan and EXP3174 closely followed their respective plasma concentrations. The apparent dissociation constant of EXP3174 to the angiotensin II receptor was estimated, based on the total plasma concentrations, to be approximately 5 times lower than that for losartan.}, number={5}, journal={JOURNAL OF CARDIOVASCULAR PHARMACOLOGY}, author={Lankford, SM and Plummer, D and Hellyer, P and Christ, DD and Bai, SA}, year={1997}, month={Nov}, pages={583–590} }
 @inproceedings{aronson_bai_riviere_aucoin_1986, title={Effects of disease on drug binding to serum proteins}, volume={3}, ISBN={0852009321}, DOI={10.1007/978-94-009-4153-3_38}, booktitle={Comparative veterinary pharmacology, toxicology, and therapy: proceedings of the 3rd Congress of the European Association for Veterinary Pharmacology and Toxicology, August 25-29, 1985, Ghent, Belgium}, publisher={Boston: MTP Press Ltd.}, author={Aronson, A. L. and Bai, S. A. and Riviere, J. E. and Aucoin, D. P.}, year={1986}, pages={407–414} }
 @article{dix_bai_rogers_anderson_riviere_1985, title={Pharmacokinetics of digoxin in sheep: Limitations of the use of biological half life for interspecies extrapolation}, volume={46}, journal={American Journal of Veterinary Research}, author={Dix, L. P. and Bai, S. A. and Rogers, R. A. and Anderson, D. L. and Riviere, J. E.}, year={1985}, pages={470–472} }